Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Health & Biotech
‘Bring in the bulldozers’: Cynata’s CEO on how heavyweight FujiFilm will turbocharge its stem cells production
Health & Biotech
ASX Health Stocks: Cynata signs deal with FujiFilm, set to produce MSC stem cells on a mass scale
Health & Biotech
ASX Health Stocks: Lumos is ready to seek regulatory approval for its COVID-19 rapid antigen test
Health & Biotech
Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have emerged
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
Here are the ASX heart stocks fighting the number one killer disease in humans
Health & Biotech
ASX Health Stocks: Immuron jumps 19pc after lead COVID-19 drug benefits published in major journal
Health & Biotech
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery
Health & Biotech
New breakthrough in stem cells research paves the way for ASX regenerative medicine stocks
Experts
ScoPo’s powerplays: Look to Mach7, Volpara and IMEXHS as quarterly reports near
Health & Biotech
Dr Boreham’s Crucible: Is Cynata’s coat of many colours about to find the perfect fit?
Health & Biotech
So, COVID vaccines are here; what now for all those biotechs working on COVID 19 drugs or tests?
Experts
MoneyTalks: This biotech focused fund explains why it invested $15m in these 2 ASX stocks
Health & Biotech
Clinical Trials Tracker: The tests ASX healthcare companies have upcoming in 2021
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
